International Journal of Antimicrobial Agents
Volume 14, Issue 3 , Pages 193-201 , April 2000

Chemistry and biological activity of new 3-benzazepines

  • Masami Kawase

      Affiliations

    • Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-492-862233; fax: +81-492-717984
    • ,
  • Setsuo Saito

      Affiliations

    • Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
    • ,
  • Noboru Motohashi

      Affiliations

    • Meiji Pharmaceutical University, Kiyose-shi, Tokyo 204-8588, Japan

References 

  1. Weinstock J, Hieble JP, Wilson JW. The chemistry and pharmacology of 3-benzazepines. Drugs Future. 1985;10:645–696
  2. Giering JE, Davidson TA, Shetty BV, Truant AP. Narcotic antagonist activity of substituted 1,2,4,5-tetrahydro-3H,3-benzazepines. Narcotic antagonists. In:  Braude MC,  Harris LS,  May EL,  Smith JP,  Villarreal JE editor. Advances in Biochemical Psychopharmacology. 8:New York: Raven Press; 1974;p. 167–186
  3. Kawase M, Motohashi N, Chakrabarty AN, et al.  Cytotoxic activity and radical intensity of 3-benzazopine derivatives. In:  Chakrabarty AN,  Molnár J,  Dastidar SG,  Motohashi N editor. Non Antibiotics. New Delhi, India: NISCOM; 1998;
  4. Molnár J, Szabo D, Miskolci C, et al.  The effect of some new 3-benzazepines on plasmid DNA, mdr P-glycoprotein and reverse transcriptase leukaemia. In:  Chakrabarty AN,  Molnár J,  Dastidar SG,  Motohashi N editor. Non Antibiotics. New Delhi, India: NISCOM; 1998;
  5. Kawase M, Motohashi N, Kurihara T, et al.  Relationship between radical intensity and cytotoxic activity of dopamine-related compounds. Anticancer Res. 1998;18:1069–1074
  6. Kametani T, Fukumoto K. Synthesis of benzazepine alkaloids and related compounds. Heterocycles. 1975;3:931–1004
  7. Kawase M, Motohashi N, Niwa M, Nozaki M. Use of the triflamide group for Friedel–Crafts acylation of N-(β-phenethyl)amino acids to 3-benzazepine derivatives. Heterocycles. 1997;45:1121–1129
  8. Kawase M, Niwa M, Nozaki M, Motohashi N. Synthesis of 2-trifluoromethyl-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. Heterocycles. 1998;48:555–560
  9. Proctor GR, Thomson RH. Azabenzocycloheptenones. Part 1. The Friedel Crafts reaction with aryl-amino-acids, J Chem Soc 1957;2302–2311.
  10. Kawase M, Okada Y, Miyamae H. The Dakin West reaction of N-acyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acids using trifluoroacetic anhydride: structural revision for the unexpected product. Heterocycles. 1998;48:285–294
  11. Davis FD, Zhou P, Reddy GV. Asymmetric synthesis and reactivities of cis-N-(ρ-toluenesulfinyl)aziridine-2-carboxylic acids. J. Org. Chem. 1994;59:3243–3245
  12. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis. 1992;11:121–139
  13. Sakagami H, Satoh K, Fukuchi K, Gomi K, Takeda M. Effect of an iron-chelator on ascorbate induced cytotoxicity. Free Radic. Biol. Med. 1997;23:260–270
  14. Satoh K, Sakagami H, Motohashi N. Radical modulation activity of benzo[a]phenothiazine. Anticancer Res. 1997;17:2539–2544
  15. Iriyama K, Yoshiura M, Iwamoto T, Ozaki Y. Simultaneous determination of uric and ascorbic acids in human serum by reversed-phase high performance liquid chromatography with electrochemical detection. Anal. Biochem. 1984;141:238–243
  16. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Stitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256:1783–1790
  17. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer. 1993;72:3553–3563
  18. Aszalos A, Pine PS, Pandey R, Gottesman MM. Behavior of N-acylated daunorubicins in mdr1 gene transfected and parental cells. Biochem. Pharm. 1995;50:889–892
  19. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989;58:137–171
  20. Li X-Z, Ma D, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob. Agents Chemother. 1994;38:1742–1752
  21. Clark FS, Parkinson T, Hitchcock CA, Gow NAR. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob. Agents Chemother. 1996;40:419–425
  22. Gollapudi S, Reddy M, Gangadharam P, Tsuruo T, Gupta S. Mycobacterium tuberculosis induces expression of P-gycoprotein in promonocytic U1 cells chronically infected with HIV type 1. Biochem. Biophys. Res. Commun. 1994;199:1181–1187
  23. Ford JM, Hait W. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 1990;42:155–199
  24. Zamora JM, Pearce HL, Beck WT. Physical chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 1988;33:454–462
  25. Tsuruo T, lida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41:1967–1972
  26. Chiba P, Ecker D, Schmid J, et al.  Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol. Pharmacol. 1996;49:1122–1130
  27. Kiue A, Sano T, Suzuki K, et al.  Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. Cancer Res. 1990;50:310–317
  28. Pajeva I, Wiese M. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J. Med. Chem. 1998;41:1815–1826
  29. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem. Pharmacol. 1992;43:109–117
  30. Dhainaut A, Regnier G, Tizot A, et al.  New purines and purine analogs as modulators of multidrug resistance. J. Med. Chem. 1996;39:4099–4108
  31. Hyafil F, Vergely C, Vignaud PD, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993;53:4595–4602
  32. Sato W, Fukazawa N, Nakanishi O, et al.  Reversal of mutidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother. Pharmacol. 1995;35:271–277
  33. Andrus MB, Lepore SD, Turner TM. Total synthesis of stipiamide and designed polyenes as new agents for the reversal of mutidrug resistance. J. Am. Chem. Soc. 1997;119:12159–12169
  34. Kessel D. Exploring multidrug resistance using rhodamine 123. Cancer Commun. 1989;1:145–149
  35. Pileblad E, Slivka A, Bratvold D, Cohen G. Studies on the autoxidation of dopamine: interaction with ascorbate. Arch. Biochem. Biophys. 1988;263:447–452
  36. Reynolds CP, Perez-Polo JR. Ascorbic acid enhances the cytotoxic effect of 6-hydroxydopamine for human neuroblastoma cell lines. Neurosci. Lett. 1981;26:151–155
  37. Thomas CE, McLean LR, Parker RA, Ohlweiler DF. Ascorbate and phenolic antioxidant interactions in prevention of liposomal oxidation. Lipids. 1992;27:543–550
  38. Driscoll JS. Catecholamine analogs as potential antitumor agents. J. Pharm. Sci. 1979;78:1519–1521
  39. Bindoli A, Rigobello MP, Deeble DJ. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol. Med. 1992;13:391–405
  40. Picardo M, Passi S, Nazzaro-Porro M, et al.  Mechanism of antitumoral activity of catechols in culture. Biochem. Pharm. 1987;36:417–425
  41. Swartz MN. Hospital-acquired infections: diseases with increasingly limited therapies. Proc. Natl. Acad. Sci. 1994;91:2420–2427
  42. Ecker G, Chiba P, Hitzler M. Structure activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance. J. Med. Chem. 1996;39:4767–4774
  43. Proudfoot JR, Hargrave KD, Kapadia SR, et al.  Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse. J. Med. Chem. 1995;38:4830–4838
  44. Artico M, Silvestri R, Pagnozzi E, et al.  5H-Pyrrolo[1,2-b][1,2,5]benzothia-diazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. 1996;4:837–850
  45. Cushman M, Casimiro-Garcia A, Williamson K, Rice WG. Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyidiarylmethane (ADAM) series with optimized potency and therapeutic index. Bioorg. Med. Chem. Lett. 1998;8:195–198

PII: S0924-8579(99)00155-7

International Journal of Antimicrobial Agents
Volume 14, Issue 3 , Pages 193-201 , April 2000

Article Tools

* Image Usage & Resolution